![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Galvus, Zavamet others |
Other names | LAF237 |
AHFS/Drugs.com | UK Drug Information |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 85% |
Protein binding | 9.3% |
Metabolism | Mainly hydrolysis to inactive metabolite; CYP450 not appreciably involved |
Elimination half-life | 2 to 3 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.712 |
Chemical and physical data | |
Formula | C17H25N3O2 |
Molar mass | 303.406 g·mol−1 |
3D model (JSmol) | |
Solubility in water | Freely Soluble in water mg/mL (20 °C) |
| |
| |
![]() ![]() |
Vildagliptin, sold under the brand name Galvus and others, is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
It was approved by the EMA in 2007.[4]
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search